CPT Proprietary Laboratory Analysis (PLA) Code Approved for the Test
Monrovia, Calif. (November 14, 2017) – InSource Diagnostics introduces ToxLok – a new genetic verification for the company’s urine drug tests, which are routinely used to monitor patients who have been prescribed high-risk medications. With the widespread use and abuse of opioid and other high-risk drugs, the incidence of patients cheating when providing urine samples has increased. With ToxLok, a simple buccal swab is collected with the urine sample and DNA markers from the swab and the urine are matched. The test can identify synthetic urine as well as samples that might be obtained from a friend or relative. In addition to revealing falsified sampling, ToxLok is a safety measure that guards against accidental mismatching of sample and patient name.
ToxLok is highly accurate, using 52 genetic markers to identify each patient and urine sample. Analysis is carried out using qPCR and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), which is widely recognized for its speed and sensitivity. The ToxLok test has been reviewed by the Centers for Medicare and Medicare Services and has received a Proprietary Laboratory Analysis (PLA) Code, which has been published by the American Medical Association and is effective October 1, 2017.
“Some patients are going to great lengths to obtain more opioids and other high-risk medications,” said Sky Countryman, CEO of InSource Diagnostics. “Consequently, there is more scrutiny on physicians who prescribe these drugs. Demand for our ToxLok test has been high among our customers, who want an extra degree of accuracy and safety.”
InSource Diagnostics is a CLIA-certified clinical diagnostic laboratory that offers a large and growing menu of blood tests, therapeutic drug monitoring and drugs-of-abuse testing. The company also develops and markets innovative blood collection devices along with genetic sample matching to detect urine substitution attempts. Founded and staffed by scientists, InSource Diagnostics is one of the largest labs in California, with a 9,720 square-foot testing facility at its headquarters in Monrovia. Founded in 2012, InSource Diagnostics serves customers nationwide.
Please send reader inquiries from this release directly to:
Link to this release at:
Contacts for the Media:
Jennifer Dahlgren, Dahlgren Communications
Sky Countryman, CEO, InSource Diagnostics